Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. Show more

Location: 2200 Bridge Pkwy, Redwood City, CA, 94065, United States | Website: https://jaspertx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

44.21M

52 Wk Range

$2.27 - $26.05

Previous Close

$2.72

Open

$2.69

Volume

123,198

Day Range

$2.58 - $2.69

Enterprise Value

6.529M

Cash

39.51M

Avg Qtr Burn

-18.37M

Insider Ownership

1.17%

Institutional Own.

78.31%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Briquilimab (SC) Details Chronic spontaneous urticaria (CSU)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab (SC) Details Cold urticaria (ColdU) or symptomatic dermographism (SD)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab Details Severe combined immunodeficiency due to complete RAG1/2 deficiency	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab (SA SC) Details Asthma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.